Melinta Gets Nod For Ch. 11 Auction Starting At $140M

Ailing antibiotics developer Melinta Therapeutics Inc. appears to have secured approval for a previously contested Chapter 11 sale plan that allows top creditor Deerfield Management Co. to serve as the opening...

Already a subscriber? Click here to view full article